| N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer E Dardenne, H Beltran, M Benelli, K Gayvert, A Berger, L Puca, J Cyrta, ... Cancer cell 30 (4), 563-577, 2016 | 522 | 2016 |
| A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers H Beltran, C Oromendia, DC Danila, B Montgomery, C Hoimes, ... Clinical Cancer Research 25 (1), 43-51, 2019 | 226 | 2019 |
| RNA helicases DDX5 and DDX17 dynamically orchestrate transcription, miRNA, and splicing programs in cell differentiation E Dardenne, MP Espinoza, L Fattet, S Germann, MP Lambert, H Neil, ... Cell reports 7 (6), 1900-1913, 2014 | 219 | 2014 |
| Cotranscriptional exon skipping in the genotoxic stress response M Dutertre, G Sanchez, MC De Cian, J Barbier, E Dardenne, L Gratadou, ... Nature structural & molecular biology 17 (11), 1358-1366, 2010 | 191 | 2010 |
| N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer A Berger, NJ Brady, R Bareja, B Robinson, V Conteduca, MA Augello, ... The Journal of clinical investigation 129 (9), 3924-3940, 2019 | 154 | 2019 |
| Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer L Puca, K Gavyert, V Sailer, V Conteduca, E Dardenne, M Sigouros, ... Science translational medicine 11 (484), eaav0891, 2019 | 148 | 2019 |
| Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness E Dardenne, S Pierredon, K Driouch, L Gratadou, M Lacroix-Triki, ... Nature structural & molecular biology 19 (11), 1139-1146, 2012 | 148 | 2012 |
| Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer M Dutertre, L Gratadou, E Dardenne, S Germann, S Samaan, R Lidereau, ... Cancer research 70 (9), 3760-3770, 2010 | 97 | 2010 |
| Dual role of the ddx5/ddx17 RNA helicases in the control of the pro-migratory NFAT5 transcription factor S Germann, L Gratadou, E Zonta, E Dardenne, B Gaudineau, M Fougère, ... Oncogene 31 (42), 4536-4549, 2012 | 79 | 2012 |
| The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways S Samaan, LC Tranchevent, E Dardenne, M Polay Espinoza, E Zonta, ... Nucleic acids research 42 (4), 2197-2207, 2014 | 69 | 2014 |
| A computational drug repositioning approach for targeting oncogenic transcription factors KM Gayvert, E Dardenne, C Cheung, MR Boland, T Lorberbaum, ... Cell reports 15 (11), 2348-2356, 2016 | 40 | 2016 |
| The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway N Madhukar, VV Prabhu, E Dardenne, F Doherty, A VanEngelenburg, ... Cancer Research 77 (13_Supplement), 2792-2792, 2017 | 5 | 2017 |
| Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer L Puca, V Sailor, K Gavyert, E Dardenne, K Isse, M Sigouros, DM Nanus, ... Cancer Research 78 (13_Supplement), 1947-1947, 2018 | 3 | 2018 |
| 35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers E Dardenne, F Padilla, S Rasmussen, SN Yang, A Mentes, LS Ogawa, ... Annals of Oncology 32, S15, 2021 | 2 | 2021 |
| BDTX-1535: A MasterKey EGFR inhibitor targeting classical and non-classical oncogenic driver mutations and the C797S acquired resistance mutation to address the evolving … E Dardenne, M O'Connor, M Nilsson, J He, X Yu, JV Heymach, X Le, ... Cancer Research 84 (6_Supplement), 1229-1229, 2024 | | 2024 |
| The identification of CELSR3 and other potential cell surface targets in neuroendocrine prostate cancer L Van Emmenis, SY Ku, K Gayvert, JR Branch, NJ Brady, S Basu, ... Cancer research communications 3 (8), 1447-1459, 2023 | | 2023 |
| Abstract B037: N-Myc driven cell plasticity in castrate-resistant prostate cancer E Dardenne, A Berger, K Gayvert, L Puca, J Elkader, B Robinson, ... Cancer Research 78 (16_Supplement), B037-B037, 2018 | | 2018 |
| N-Myc driven cell plasticity in castrate-resistant prostate cancer E Dardenne, A Berger, K Gayvert, L Puca, J Elkader, B Robinson, ... CANCER RESEARCH 78 (16), 98-99, 2018 | | 2018 |
| N-Myc drives neuroendocrine prostate cancer E Dardenne, H Beltran, K Gayvert, M Benelli, A Berger, L Puca, J Cyrta, ... Cancer Research 76 (14_Supplement), 887-887, 2016 | | 2016 |
| Abstract PR08: The N-Myc transcriptional program driving the neuroendocrine prostate cancer phenotype E Dardenne, K Gayert, A Sboner, C Cheung, M Eilers, M Rubin, H Beltran, ... Molecular Cancer Therapeutics 13 (10_Supplement), PR08-PR08, 2015 | | 2015 |
Olivier ElementoDirector, Englander Institute for Precision Medicine, Weill Cornell Medicine在 med.cornell.edu 的电子邮件经过验证
